Prof. Esther Priel
Born: 1952, Israel
Academic Qualifications:
    D.Sc. 1981, Technion, Haifa
    Senior Lecturer 1993.
Academic Positions:
The Shraga Segal Department of Microbiology, Immunology and Genetics - Associate Professor

Research Interests:
The activity and regulation of DNA topoisomerases in cancer stem cells..The involvement of DNA topoisomerases in the retroviruses life cycle and the effect of topoisomerase inhibitors on the replication of retroviruses.
topoisomerases and telomerase in diabetes. Topoisomerase and telomerase in human fertility. Telomerase and telomerase activators in stem cells
Telomerase and telomerase activators in the brain and in neurodegenerative diseases (including ALS)
Research Projects:
Novel compounds that activate telomerase in human stem cells and their effect in neurodegenerative diseases using animal models
Patents:
  • 3. Inventors: Priel Esther, Gazit Aviv, Itzhak Shara, Slavin Shimon , Tri-phenyl compounds and compositions comprising the same. , P-9850-USP , 2007
  • 5. Priel Esther, Gazit Aviv, Itzhak Shara, Slavin Shimon field , Enhanced sensitivity polymerase chain reactions: , P-9405 USP, 2007
  • 4. Inventors: Priel Esther, Gazit Aviv, Itzhak Shara, Slavin Shimon. , Telomerase activating compounds and methods of use thereof. , P-9406 USP, US serial no: 601924875 , 2007
  • Inventors: Alex Levitsky, Aviv Gazit and Esther Priel. , "Tyrphostins and Pharmaceutical Compositions Containing Them" , Israeli Patent 110570 filed, 1994
  • . Inventor: Esther Priel, Co-inventors: Stephen D. Showalter and Donald G. Blair. 1990, filed 5/8/1990 approved 1994., "Method for treating retroviral infections in mammals"., U.S. Patent 07/250,456,, 1994
Abstracts of Current Research:
  • Certain tyrphostin derivatives as topoisomerases inhibitors and anti-cancer drugs.: We have found that certain tyrphostin derivatives, which are known as protein tyrosine kinase antagonists, inhibit DNA topoisomerase I activity. Their mode of action differs from the known topoisimerase inhibitors. Since topoisomerase inhibitors are known as affective anti-cancer drugs, our results suggest that those tyrphostin derivatives that inhibit topoisomerase activity may serve as potent anti-cancer drugs due to their ability to inhibit both protein tyrosine kinases and topoisomerases. In addition, these results suggest that it will be possible to use them when resistance to known anti-topoisomerase drugs occur, thus providing an alternative way for cancer treatment.
  • Method of treating retroviral infections in mammals: We have found that DNA topoisomerase I activity is present in retroviral particles such as HIV, EIAV, Mo-MuLV, HTLV-I.In vitro and in vivo studies demonstrated that non-cytotoxic doses of camptothecin, a specifictopoisomerase antagonist, or certain tyrphostin derivatives significantly inhibitedthe replication of these retroviruses in acute and chronically infected cells at a very high efficacy. Our data indicate that these drugs can act as anti retroviral drug in vitro.We evaluated their efficacy in vivo using murine retroviruses (Mo-MuLV, SFFV, MAIDS). Mice were infected with the appropriate virus and the drugs were administered at different doses and at different times after or during virus injection. Our data clearly demonstrate that camptothecin or tyrphostin prevented and inhibited the onset of retroviral induced diseases in mice without causing any visible toxic side effects.Our results suggest that camptothecin or certain tyrphostin derivatives might be considered a valid remedy for the treatment of retroviral diseases.
Publications:
  • Schavinsky-Khrapunsky Y, Priel E, Aboud M. . Dose-dependent dual effect of HTLV-1 tax oncoprotein on p53-dependent nucleotide excision repair in human T-cells. Int J Cancer 122(2):: 305-16. (2008)
  • Reuveni D, Halperin D, Shalit I, Priel E, Fabian I. 2008 Mar 15;. Epub 2007 Dec 3.. Quinolones as enhancers of camptothecin-induced cytotoxic and anti-topoisomerase I effects. Biochem Pharmacol. 75(6):: 1272-81 (2008)
  • Har-Vardi I, Mali R, Breietman M, Sonin Y, Albotiano S, Levitas E, Potashnik G, Priel E. . DNA topoisomerases I and II in human mature sperm cells: characterization and unique properties. Hum Reprod. 22(8):: 2183-9 (2007)
  • Kogan NM, Schlesinger M, Priel E, Rabinowitz R, Berenshtein E, Chevion M, Mechoulam R. . 2007 Jan;. HU-331, a novel cannabinoid-based anticancer topoisomerase II inhibitor. Mol Cancer Ther 6(1):: 173-83. (2007)
  • Noach N, Segev Y, Levi I, Segal S, Priel E. 2007 Dec;. Epub 2007 Oct 11.. Modification of topoisomerase I activity by glucose and by O-GlcNAcylation of the enzyme protein. Glycobiology. 17(12):: 1357-64 (2007)
  • Cohen-Armon M, Visochek L, Priel E, Ishay JS. . A fatal effect of hornet venom on rat-brain cortical neurons. Chem Biodivers. 3(5):: 535-43 (2006)
  • Fabian I, Reuveni D, Levitov A, Halperin D, Priel E, Shalit I. . Moxifloxacin enhances antiproliferative and apoptotic effects of etoposide but inhibits its proinflammatory effects in THP-1 and Jurkat cells. Br J Cancer. 95(8):: 1038-46. (2006)
  • Plaschkes I, Silverman FW, Priel E. . DNA topoisomerase I in the mouse central nervous system: Age and sex dependence. J Comp Neurol. 493(3):: 357-69. (2005)
  • Visochek L, Steingart RA, Vulih-Shultzman I, Klein R, Priel E, Gozes I, Cohen-Armon M. . PolyADP-ribosylation is involved in neurotrophic activity. J Neurosci. 25(32):: 7420-8. (2005)
  • Azran I, Schavinsky-Khrapunsky Y, Priel E, Huleihel M, Aboud M. . Implications of the evolution pattern of human T-cell leukemia retroviruses on their pathogenic virulence (Review). Int J Mol Med. 14(5):: 909-15. (2004)
  • Bendetz-Nezer S, Gazit A, Priel E. . DNA topoisomerase I as one of the cellular targets of certain tyrphostin derivatives. Mol Pharmacol. 66(3):: 627-34 (2004)
  • Argaman M, Bendetz-Nezer S, Matlis S, Segal S, Priel E. 2003 Feb 14;. Revealing the mode of action of DNA topoisomerase I and its inhibitors by atomic force microscopy. Biochem Biophys Res Commun. 301(3):: 789-97 (2003)
  • Sklan EH, Gazit A, Priel E. . Inhibition of murine AIDS (MAIDS) development in C57BL/6J mice by tyrphostin AG-1387. Virology. 278(1):: 95-102. (2000)
  • Homburg S, Visochek L, Moran N, Dantzer F, Priel E, Asculai E, Schwartz D, Rotter V, Dekel N, Cohen-Armon M. . A fast signal-induced activation of Poly(ADP-ribose) polymerase: a novel downstream target of phospholipase c. J Cell Biol. 150(2):: 293-307. (2000)
  • Chechlnitsky, G. & Priel, E.. DNA bindibg properties of the nucleocapsid protein from human T cell leukemia virus type I. Int. J. Oncology 13: 749-755 (1998)
  • Seri, I. & Priel, E.. The p15 matrix protein of moloney murine leukemia virus is a phosphotyrosine protein. FEBS Letters 392: 229-232 (1997)
  • Seri, I., Aflalo, E., Gazit, A. & Priel, E.. Tyrphostin AG-555 inhibit early and late stages of moloney murine leukemia virus replication cycle. Int. J. Oncology 10: 1185-1189 (1997)
  • Fishman, D., Galitski, L., Priel, E. & Segal, S.. Epidermal growth factor regulates protein kinase A activity in murine fibrisarcoma cells: differences between metastatic and non-metastatic tumor cell variants. Cancer Res. 57: 5410-5415 (1997)
  • Horowitz, S., Maor, R. & Priel, E.. Characterization of topoisomerase activity in two strain of M. fermentans and in M. pirum. J. Bacteriology 179: 6626-6632 (1997)
Keywords:DNA Topoisomerase, DNA topoisomerases, telomerase, Molecular Biology, Brain research, stem cells, alzheimer, telomerase, Cancer, Retroviruses, DNA Repair.
Phones:
    Email:priel@bgu.ac.il